Long non-coding RNA XIST predicts worse prognosis in digestive system tumors: a systemic review and meta-analysis. Issue 3 (21st June 2018)

• Record Type: Journal Article
• Authors: Liu, Xuefang; Ming, Xinliang; Jing, Wei; Luo, Ping; Li, Nandi; Zhu, Man; Yu, Mingxia; Liang, Chunzi; Tu, Jiancheng
• Is Part Of: Bioscience reports. Volume 38:Issue 3(2018)
• Publication Date: 2018-06-21
• Subjects: clinicopathological characteristic -- LncRNA -- prognosis -- XIST; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20180169
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract : Increasing studies are indicating that long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) is associated with the prognosis of cancer patients. However, the results have been disputed. Therefore, we aimed to further explore the prognostic value and clinical significance of XIST in various types of cancers. Then, we focussed our research on the comparison of the predictive value of XIST between digestive system tumors and non-digestive system tumors. We performed a systematic search by looking up PubMed, Embase, Cochrane Library, Web of Science, and Medline (up to 3 January 2018). Fifteen studies which matched our inclusion criteria with a total of 920 patients for overall survival and 867 patients for clinicopathological characteristics were included in this meta-analysis. Pooled hazard ratios (HR) and odds ratios (ORs) with their corresponding 95% confidence intervals (95% CIs) were calculated to summarize the effects. Our results suggested that high expression levels of XIST were associated with unfavorable overall survival in cancer patients (pooled HR = 1.81, 95% CI: 1.45–2.26). Additionally, we found that XIST was more valuable in digestive system tumors (pooled HR = 2.24, 95% CI: 1.73–2.92) than in non-digestive system tumors (pooled HR = 1.22, 95% CI: 0.60–2.45). Furthermore, elevated expression levels of XIST were connected with distant metastasis and tumor stage. XIST was correlated with poor prognosis, which suggested that XIST might serve as a novel predictive biomarker for cancer patients, especially for patients of digestive system tumors.